Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Etelcalcetide (Primary) ; Cinacalcet
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Amgen
- 01 Nov 2017 Planned End Date changed from 11 Apr 2019 to 19 Jul 2019.
- 01 Nov 2017 Planned primary completion date changed from 11 Apr 2019 to 19 Jul 2019.
- 01 Nov 2017 Planned initiation date changed from 31 Jan 2018 to 1 Apr 2018.